MiMedx Comments On Matters Related To Former VA Employees
Although the indictment does reference speaker fees paid by the Company to the former VA employees who were indicted and other interactions between persons who were
The Company is actively reviewing the information outlined in the indictment. Furthermore, the Company has fully cooperated with the
The Company maintains a robust compliance program that, among other processes and procedures, monitors the activities of our sales representatives. Those who do not comply with the Company's policies and procedures are subject to disciplinary action.
The indictment includes allegations against the named individuals regarding the payment of speaker fees by the Company. On occasion,
On previous occasions,
It is the Company's opinion that it has a well-respected product line in the VA and the
MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind the Company's mission to give physicians products and tissues to help the body heal itself. The Company processes the human placental tissue utilizing its proprietary PURION® Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization.
Safe Harbor Statement
This press release includes forward-looking statements. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements.
Actual results may differ from those set forth in the forward-looking statements. For more detailed information on the risks and uncertainties, please review the Risk Factors section of the Company's most recent annual report or quarterly report filed with the
Robert P. Borchert, Vice President, Investor Relations, 770-651-9383, email@example.com